|
|
(10.) The Gut Microbiome and Responses to Neoadjuvant Chemoradiation in Rectal Cancer Patients
|
5R21CA205636-02
|
$202,275
|
$101,138
|
CHEN, GRACE
|
UNIVERSITY OF MICHIGAN
|
|
|
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities
|
1R01CA216290-01
|
$338,903
|
$338,903
|
PYTER, LEAH
|
OHIO STATE UNIVERSITY
|
|
|
(PQ #4) Single cell barcoding for studies of study clonal evolution in glioblastoma
|
5R01CA190121-05
|
$362,088
|
$119,489
|
VERHAAK, ROELAND
|
JACKSON LABORATORY
|
|
|
(PQ 9) Dysregulation of epidermal MMP-13 as cause of paclitaxel-induced peripheral neuropathy
|
1R01CA215973-01
|
$443,022
|
$443,022
|
RIEGER, SANDRA
|
MOUNT DESERT ISLAND BIOLOGICAL LAB
|
|
|
(PQ#9): Altered mitochondrial transport and chemotherapy-induced peripheral neuropathy
|
1R21CA215985-01
|
$198,000
|
$198,000
|
CHANG, KAREN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
5R01CA206025-02
|
$637,172
|
$637,172
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
|
5R21CA205644-02
|
$202,439
|
$202,439
|
WHITESIDE, THERESA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
1R01CA219880-01
|
$697,539
|
$348,770
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
1R21CA217137-01
|
$209,093
|
$209,093
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
5R01CA205967-02
|
$386,588
|
$386,588
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
|
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
|
5R01CA205101-02
|
$388,402
|
$388,402
|
SKALA, MELISSA
|
MORGRIDGE INSTITUTE FOR RESEARCH, INC.
|
|
|
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae
|
5R01CA208634-02
|
$560,277
|
$560,277
|
JURECIC, ROLAND
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle
|
5R21CA205437-03
|
$168,236
|
$168,236
|
WANING, DAVID
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
|
(PQ9) Prevention of Bleomycin-induced Pulmonary Toxicity by Dichloroacetate (DCA)
|
5R21CA208746-02
|
$173,586
|
$173,586
|
KIM, JUNG-WHAN
|
UNIVERSITY OF TEXAS DALLAS
|
|
|
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
|
5R01CA205255-02
|
$577,463
|
$577,463
|
SEGAL, ROSALIND
|
DANA-FARBER CANCER INST
|
|
|
(PQ9)A redox-mediated mechanism of chemotherapy-induced cognitive impairment
|
1R01CA217934-01
|
$455,149
|
$455,149
|
ST CLAIR, DARET
|
UNIVERSITY OF KENTUCKY
|
|
|
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy
|
1R01CA205166-01A1
|
$536,312
|
$536,312
|
KELLEY, MARK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
|
5R01CA184922-04
|
$553,684
|
$276,842
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
|
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers
|
5R01CA184968-04
|
$509,161
|
$254,581
|
SIKIC, BRANIMIR
|
STANFORD UNIVERSITY
|
|
|
(PQD5) A novel genetic strategy to predict efficacy of anti-CD20 antibodies
|
5R01CA185372-04
|
$321,625
|
$321,625
|
RICHARDS, KRISTY
|
CORNELL UNIVERSITY
|
|
|
(PQD5) Avatar-directed Treatment for Ovarian Cancer
|
5R01CA184502-04
|
$714,297
|
$714,297
|
WEROHA, SARAVUT
|
MAYO CLINIC ROCHESTER
|
|
|
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling
|
5R01CA185353-04
|
$405,890
|
$405,890
|
KIM, WILLIAM
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
$1,992
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
|
1/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
|
5U54CA156734-07
|
$1,700,705
|
$102,042
|
COLON-CARMONA, ADAN
|
UNIVERSITY OF MASSACHUSETTS BOSTON
|
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-08
|
$919,471
|
$73,558
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
2/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
|
5U54CA156732-07
|
$1,834,682
|
$256,855
|
VISWANATH, KASISOMAYAJULA
|
DANA-FARBER CANCER INST
|
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118623-12
|
$407,680
|
$12,230
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
|
2D and 3D Contrast-enhanced Ultrasound Evaluation of HCC Chemoembolization
|
5R01CA194307-02
|
$548,690
|
$548,690
|
EISENBREY, JOHN
|
THOMAS JEFFERSON UNIVERSITY
|
|
|
3D Dynamic Contrast-Enhanced US for Monitoring Chemotherapy of Liver Metastasis
|
5R01CA195443-02
|
$252,908
|
$126,454
|
WILLMANN, JUERGEN
|
STANFORD UNIVERSITY
|
|
|
A functional genomics approach to determine the mechanism of cellular response to new anti-cancer
|
4R00CA204602-02
|
$249,000
|
$249,000
|
GILBERT, LUKE
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
A network platform to connect drug response and prognosis phenotypes for cancers
|
5R01CA196631-02
|
$395,911
|
$395,911
|
LI, HU
|
MAYO CLINIC ROCHESTER
|
|
|
A novel combinatorial approach for treating HPV-associated malignancies
|
1R43CA221479-01
|
$191,115
|
$191,115
|
FILIPPOVA, MARIA
|
ISPIN, INC.
|
|
|
A NOVEL EXTRACELLULAR AND INTRACELLULAR TREATMENT PARADIGM FOR ERADICATING CANCER
|
5F30CA189435-04
|
$49,044
|
$49,044
|
SOM, AVIK
|
WASHINGTON UNIVERSITY
|
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-03
|
$473,915
|
$236,958
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A Novel PET Probe for Use in Cancer Diagnostics
|
2R44CA216539-02
|
$997,667
|
$329,230
|
MOORE, MELISSA
|
SOFIE BIOSCIENCES, INC.
|
|
|
A p53/NFkB-mediated metabolic mechanism for chemotherapy protection
|
5R01CA183074-04
|
$335,113
|
$335,113
|
YUAN, ZHI-MIN
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
|
|
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
|
1R44CA217591-01
|
$621,000
|
$621,000
|
KAHN, STUART
|
SYNTRIX BIOSYSTEMS, INC.
|
|
|
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome
|
1R44CA213519-01
|
$999,914
|
$999,914
|
ISAACMAN, STEVEN
|
NANOMETICS, LLC
|
|
|
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy
|
5R44CA206606-02
|
$1,004,186
|
$1,004,186
|
WINRAM, SCOTT
|
CYNVEC, LLC
|
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-03
|
$1
|
$1
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
A Phase I trial combining IV fenretinide and IV safingol to target overproduction
|
4R44CA183316-02
|
$648,029
|
$648,029
|
SIMPSON, WILLIAM
|
CERRX, INC.
|
|
|
A Prospective Study of the Impact of Breast Cancer on Symptoms and Functioning
|
5R01CA199137-03
|
$392,439
|
$129,505
|
AVIS, NANCY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
|
A Question Prompt List to Promote Communication in Genomic Medicine
|
5R21CA201827-02
|
$172,029
|
$86,015
|
O'NEILL, SUZANNE
|
GEORGETOWN UNIVERSITY
|
|
|
A randomized trial of lifestyle guidelines on breast cancer biomarkers and treatment adherence
|
1R01CA207753-01A1
|
$675,231
|
$675,231
|
SANFT, TARA
|
YALE UNIVERSITY
|
|
|
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
|
1U01CA217885-01
|
$1,011,983
|
$1,011,983
|
TAMAYO, PABLO
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
|
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
|
5R01CA169519-05
|
$311,250
|
$311,250
|
SALVEMINI, DANIELA
|
SAINT LOUIS UNIVERSITY
|
|
|
Aberrant signaling in acute myeloid leukemia
|
3R01CA204396-02S1
|
$232,133
|
$232,133
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Aberrant signaling in acute myeloid leukemia
|
5R01CA204396-02
|
$459,674
|
$459,674
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S1
|
$125,000
|
$7,500
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S2
|
$62,491
|
$3,749
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Total relevant funding to Chemotherapy for this search: $317,746,569
|
